Azithromycin Has Lung Barrier Protective Effects in a Cell Model Mimicking Ventilator-Induced Lung Injury

Jon P. Joelsson1,2, Iwona T. Myszor3, Snaevur Sigurdsson1, Fredrik Lehmann4, Clive P. Page4,5, Gudmundur H. Gudmundsson3, Thorarin Gudjonsson1,2 and Sigurbergur Karason1,6

1Stem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland; 2Department of Laboratory Hematology, Landspitali-University Hospital, Reykjavík, Iceland; 3Life and Environmental Sciences, BioMedical Center, University of Iceland, Reykjavík, Iceland; 4EpiEndo Pharmaceuticals, Reykjavík, Iceland; 5Sackler Institute of Pulmonary Pharmacology, King’s College London, London, UK; 6Landspitali-University Hospital, Intensive Care Unit, Reykjavík, Iceland

Abstract
Azithromycin (AZM) is a broad-spectrum antibiotic widely used to treat infections. AZM also has been shown to have anti-inflammatory and immunomodulatory functions unrelated to its antibacterial activity that contribute to the effectiveness of this drug in chronic respiratory diseases. The mechanisms behind these beneficial effects are not yet fully elucidated. We have previously shown that AZM enhances barrier integrity of bronchial epithelial cells and directs them towards epidermal differentiation. In this study, we analyzed the effect of AZM pre-treatment of human bronchial and alveolar derived cell lines on mechanical stress in a cyclical pressure air-liquid interface device (CPAD) that models the disruption of the epithelial barrier with increased inflammatory response in lung tissue, which is associated with ventilator-induced lung injury (VILI). Immunostaining and electron microscopy showed that barrier integrity of the epithelium was compromised by cyclically stressing the cells but maintained when cells had been pre-treated with AZM. Lamellar body formation was revealed in AZM pre-treated cells, possibly further supporting the barrier enhancing effects. RNA sequencing showed that the inflammatory response was attenuated by AZM treatment before cyclical stress. YKL-40, an emerging inflammatory marker, increased both due to cyclical stress and upon AZM treatment. These data confirm the usefulness of the CPAD to model ventilator-induced lung injury and suggest that AZM has barrier protective and immunomodulatory effects, attenuating the inflammatory response during mechanical stress, and might therefore be lung protective during mechanical ventilation. The model could be used to assess further drug candidates that influence barrier integrity and modulate inflammatory response.

1 Introduction
Azithromycin (AZM) is a broad-spectrum macrolode antibiotic used to treat bacterial infections, mainly of the respiratory system. The antibacterial effects of AZM are mediated through binding to the 50S subunit of the bacterial ribosome (Champney and Burdine, 1998; Champney et al., 1998; Hansen et al., 2002). However, there is increasing evidence that AZM has other pharmacological effects beyond its antibacterial activity, as it improves the health of patients suffering from chronic airway diseases such as chronic obstructive lung disease (COPD), bronchitis obliterans (BO), diffuse panbronchiolitis (DPB), asthma and cystic fibrosis (CF) (Gibson et al., 2017; Gottfried, 2004; Kawamura et al., 2017; Naderi et al., 2018; Pomares et al., 2018; Principi et al., 2015; Ramos and Criner, 2014) when used continuously.

Our group has shown that AZM enhances epithelial barrier integrity in air-liquid interface (ALI) cultures and protects against bacterial infections (Asgrimsson et al., 2006; Halldorsson et al., 2010). We have also shown that AZM treatment causes bronchial epithelial cells to differentiate towards an epidermal phenotype, along with forming multivesicular and lamellar bodies, and that saturated lipids conjugate to the AZM molecule when it enters the cell (Arason et al., 2019).
Acute respiratory distress syndrome (ARDS) is a serious condition of severe respiratory failure with high mortality commonly encountered among critically ill patients in intensive care units (ICUs). ARDS is characterized by alveolar-capillary barrier failure in the distal bronchi and alveoli, and the expansion of resident macrophages that release signals prompting a response from inflammatory cells in the nearby pulmonary vasculature. This is followed by fluid accumulation or a complete collapse of the alveolar sacs, resulting in loss of gas exchange and inadequate aeration (Thompson et al., 2017). During mechanical ventilation (MV), air is forced into the lungs, which can lead to damage of the lung epithelium due to mechanical stress and ultimately, in some cases, ventilator-induced lung injury (VILI) (Slutsky and Ranieri, 2013). MV can therefore exacerbate ARDS by causing further lung injury.

Clinical research on VILI/ARDS is challenging due to the high-risk nature of invasive diagnostic procedures in patients with such severe respiratory failure. Access to patient lung samples is therefore limited, and although there are numerous in vitro stress-inducing lung models (Huh, 2015; Karadottir et al., 2015; Ressler et al., 2000; Shiomi et al., 2011; Yu and Li, 2017; Zhao et al., 2014), they are restricted mimics of events in human lungs during ARDS or VILI because of the cyclical nature of MV.

In a recent paper, we described a device referred to as a cyclical pressure air-liquid interface device (CPAD) (Joelsson et al., 2019) in which cultures of human lung cells cultured at ALI are exposed to cyclical pressure to model MV. This device aims to replace animal experiments on MV and VILI with a human-relevant system that allows mechanistic investigation.

In this work, we use the CPAD to cyclical stress bronchial and alveolar cell lines in ALI cultures and show that, whereas untreated cells present a disrupted phenotype following mechanical strain, AZM maintains the barrier integrity in both cell lines. We observed vesicle and lamellar body formations in CPAD stressed cells which was exaggerated in AZM pre-treated cells. We also show that AZM pre-treatment attenuates the inflammatory response in CPAD stressed cells.

2 Methods

Cell culture

Two cell lines were used in this research. VA10 (Halldorsson et al., 2007) was cultured in animal origin-free Bronchial/Tracheal Epithelial Cell Medium (Cell Applications, 511A-500) supplemented with retinoic acid (Cell Applications, 511-RA), and hAELVi (Kuehn et al., 2016) was cultured in Human Airway Epithelial Cell Medium (InSCREENEX, INS-ME-1013). Both cell lines were supplemented with Penicillin (20 IU/mL)/Streptomycin (20 µg/mL) (Life Technologies, 15140122). The cell culture medium used for cell differentiation of VA10 cells in ALI cultures was Dulbecco’s Modified Eagle Medium F-12 Nutrient Mixture (DMEM/F12, Thermo Fisher Scientific) which was supplemented with 2% Ultroser G (PALL). All cell cultures were screened bi-monthly for Mycoplasma contamination by way of Phenol/Chloroform extraction (all negative).

Both cell lines were cultured at the air-liquid interface (ALI) on 12 mm diameter Transwell™ filter inserts (Corning 0.4 µm) pre-coated with collagen IV (Sigma, C7521) for the VA10 cell line and huAEC coating solution (InSCREENEX, INS-SU-1018) for the hAELVi cell line. 200.000 cells were seeded per transwell filter. Cell lines were cultured for three weeks with or without 25 µg/mL AZM (Zithromax, dissolved in 96% ethanol).

Trans-epithelial electrical resistance (TEER) was measured every other day. For this, medium was added to the apical side and resistance was measured using a Millicell ERS-2 Volt-Ohm meter.

Cyclical pressure ALI device

Both cell lines were cultured for 3 weeks with or without AZM supplementation. Half of the wells containing the cell layers were then placed in the CPAD for cyclical stressing for 24 h. The cyclical stress conditions were set according to our previous study (Joelsson et al., 2019) with peak pressure at 27 cm H2O and end-expiratory pressure at 5 cm H2O, creating a driving pressure of 22 cm H2O, with a respiratory rate of 16 breaths/min. The cyclical stress profile used in this study has a pressure difference that would produce ventilator induced lung injury (VILI) in clinical circumstances. For the purposes of clarity, combinations of the following terms are used to describe the treatment conditions: no treatment = CON, Azithromycin pre-treatment = AZM, No stress = Static and 27 cm H2O cyclical stress = Stress.

RNA sequencing and gene expression analysis

RNA was isolated from cells using TRIzol reagent (Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s protocol. RNA sequencing was performed at BGI Genomics. We quantified the RNA transcript expression with Kallisto version 0.45.0 (Bray et al., 2016) using the Ensembl v94 reference transcriptome (Yates et al., 2016). Gene expression estimates were computed with the sleuth R package v0.30 (Pimentel et al., 2017). Gene set enrichment analysis was performed with GSEA software v4.0.1 (Mootha et al., 2003; Subramanian et al., 2005). Pre-ranked gene lists were prepared by ordering the genes by expression difference significance (q-value multiplied with the sign of the log-fold change) and tested for enrichment in the MSigDB hallmark gene set collection (Liberzon et al., 2015). Significantly differentially expressed genes were uploaded to PANTHER gene ontology classification system using a statistical overrepresentation test and biological process annotation data set.

All qPCRs were performed as previously reported (Joelsson et al., 2019). Primers used are listed in Tab. S1.

Protein analysis

15 µg total protein was separated using a NuPAGE 4-12% Bis-Tris gradient gel (Life Technologies, NP0323). Primary antibodies used: mouse anti-chitinase-3-like protein 1 (YKL-40) (Milipore, MABC196); rabbit anti-IκBa (Cell Signaling Technolo-
Secondary antibodies conjugated with horse radish peroxidase (HRP) (goat anti-rabbit IgG, Sigma, A0545; goat anti-mouse IgG, Millipore, AP181P) were used. Conditioned medium from cell culture was analyzed by sandwich enzyme-linked immunosorbent assays (ELISAs) using an interleukin 8 (IL-8) assay kit (Peprotech, UK).

Confocal imaging
Samples were fixed in formalin and embedded in paraffin, then sectioned and immunostained. Antibodies used were rabbit anti-NFkB p65 (Santa Cruz Biotechnology, sc-372), mouse anti-E-Cadherin (BD Transduction Laboratories, 610182), mouse anti-chitinase-3-like protein 1 (YKL-40) (Millipore, MAB196), rabbit anti-surfactant protein B (Abcam, ab40876). Appropriate secondary antibodies were purchased from ThermoFisher. Counterc staining was done using DAPI (1:5000) (Sigma-Aldrich). Phalloidin (1:40) used for actin staining was from ThermoFisher (A22283). A list of secondary antibodies used is provided in Table S21. Immunofluorescence was imaged using an Olympus FX1200 confocal microscope (Olympus, Tokyo, Japan). Pixel intensity quantifications were calculated with ImageJ.

Transmission electron microscopy
Cell layers were fixed with 2.5% glutaraldehyde for 20 min followed by washing. Cells were dehydrated and then embedded in resin. 100 nm sections were cut by ultramicrotome. Sections were stained with lead citrate and imaged using a JEM-1400PLUS PL Transmission Electron Microscope.

Statistical analysis
For determining statistical significance analysis, a two-way ANOVA was utilized and calculated using GraphPad Prism 8.0. Error bars represent the standard deviation (SD).

3 Results

3.1 Azithromycin pre-treatment maintains barrier integrity in cyclically stressed bronchial and alveolar lung epithelial cell lines

VA10 bronchial cells
VA10 bronchial cell lines exhibited increased TEER when treated with AZM (Fig. S1A) as reported previously by (Arason et al., 2021).
When the cell layer was cyclically stressed (CON/Stress), it started to form vesicles, and a disruption of the polarized uniform phenotype was detected with wider gaps between cells (Fig. 1Aiii) (Joelsson et al., 2019). When the cells were treated with AZM (AZM/Static) for the duration of the ALI culture, the cell layer became thicker (Arason et al., 2019), and vesicles and lamellar bodies (LB) appeared (Fig. 1Aiii). When AZM pre-treated cell layers were stressed (AZM/Stress), the vesicles and LBs along with the thicker layer were observed, but not the disrupted phenotype (Fig. 1Aiii).

**hAEli alveolar cells**
The recently established hAEli cell line (Kuehn et al., 2016) was used to analyze the effect of AZM treatment and cyclical stress on an alveolar-derived cell line. AZM treatment resulted in no significant difference in TEER measurements (Fig. S1B1). Actin staining with phalloidin of ALI-cultured VA10 cells displayed a grid-like formation (Fig. 1Ai, upper left). Cyclically stressing VA10 cell layers resulted in a disruption of this structure along with aggregation of actin filaments (Fig. 1Ai, upper right). AZM treatment of VA10 cell layers showed the same grid-like form of the lung epithelial layer as seen in the control cells (Fig. 1Ai, lower left). Importantly, AZM treatment consistently resulted in larger cells, possibly due to changes in lipid metabolism, as seen previously in VA10 cells (Arason et al., 2019). Cyclically stressing AZM pre-treated cell layers maintained this structure without aggregation or disruption of actin (Fig. 1Ai, lower right).

Similar effects were observed when cell layers were stained for E-cadherin: The E-cadherin signal was diminished compared to controls in cyclically stressed cells (CON/Static), but AZM pre-treatment retained the unstressed control phenotype in both the unstressed (AZM/Static) and cyclically stressed cell layers (AZM/Stress) (Fig. 1Aii).

When viewed in the electron microscope, VA10 ALI cultured cells (CON/Static) presented a polarized uniform cell layer (Fig. 1Aiii). When the cell layer was cyclically stressed (CON/Stress), it started to form vesicles, and a disruption of the polarized uniform phenotype was detected with wider gaps between cells (Fig. 1Aiii) (Joelsson et al., 2019). When the cells were treated with AZM (AZM/Static) for the duration of the ALI culture, the cell layer became thicker (Arason et al., 2019), and vesicles and lamellar bodies (LB) appeared (Fig. 1Aiii). When AZM pre-treated cell layers were stressed (AZM/Stress), the vesicles and LBs along with the thicker layer were observed, but not the disrupted phenotype (Fig. 1Aiii).
3.2 AZM attenuates inflammatory response in mechanically stressed VA10 cell layers – RNA sequencing analysis

We have previously shown that TNFα and IL8 expression was increased in the CPAD model using bronchial epithelial lung cell lines (Joelsson et al., 2019), and it has been reported that AZM treatment has anti-inflammatory effects in airway epithelial cells (Cigana et al., 2006). Accordingly, we analyzed the effects of AZM treatment on cyclically stressed epithelial cells in the CPAD system. For this purpose, we compared RNA sequenced VA10 cells that had been cultured at ALI for three weeks with or without AZM treatment, then subjected to 27 cm H₂O stress for 24 h in the CPAD or cultured in static conditions.

Running a gene set enrichment analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) on the cells exposed to the two experimental conditions showed that cyclically stressing the untreated cells resulted in considerable enrichment of genes connected to inflammatory-associated gene sets (Fig. 3A). The pathways with the highest normalized enrichment scores (NES) showed significant positive correlation to interferon (IFN)α response, IFNγ response, TNFα signaling via NFκB, inflammatory response, complement system response, and cholesterol homeostasis gene sets (Fig. 3A).

GSEA of AZM pre-treated cells exposed to CPAD stress (AZM/Stress) compared to CON/Static, however, showed that some different gene sets were involved in the highest NES scores, showing positive correlation with oxidative phosphorylation, cholesterol homeostasis, MTORC signaling, IFNα response, MYC target V1 and protein secretion gene sets (Fig. 3B and Fig. S2). Some pathways, such as the IFNα gene pathway, were enriched in both conditions, but the NES for the inflammation related...
Fig. 3: Pre-treatment with azithromycin results in an attenuated inflammatory response in mechanically stressed VA10 cell layers – RNA sequencing analysis. Significant (nominal p-value ≤ 0.05) gene set enrichment plots that resulted from comparing conditions are shown: A) CON/Static vs CON/ Stress; B) CON/Static vs AZM/ Stress;
C) CON/Stress vs AZM/Stress;
D) CON/Static vs AZM/Static;
### Tab. 1: List of over-represented gene ontology (GO) groups in A) CON/Static vs CON/Stress and B) CON/Static vs AZM/Stress pretreated VA10 cell layers

RNA sequencing data was uploaded into the Panther gene ontology database. Only genes with a q-value of ≤ 0.05 and a fold change of ≥ 2 were uploaded. The 33 Panther GO categories with the highest fold enrichment are shown.

<table>
<thead>
<tr>
<th>GO biological process complete</th>
<th>Fold enrichment</th>
<th>Raw P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>regulation of type III interferon production (GO:0034344)</td>
<td>65.82</td>
<td>6.42E-05</td>
</tr>
<tr>
<td>wound healing involved in inflammatory response (GO:0002246)</td>
<td>32.91</td>
<td>2.61E-04</td>
</tr>
<tr>
<td>neural crest cell migration involved in autonomic nervous system development (GO:1901166)</td>
<td>32.91</td>
<td>2.61E-04</td>
</tr>
<tr>
<td>ISG15-protein conjugation (GO:0032020)</td>
<td>32.91</td>
<td>2.61E-04</td>
</tr>
<tr>
<td>detection of virus (GO:0009597)</td>
<td>32.91</td>
<td>2.61E-04</td>
</tr>
<tr>
<td>cytoplasmic pattern recognition receptor signaling pathway in response to virus (GO:0039528)</td>
<td>32.91</td>
<td>2.61E-04</td>
</tr>
<tr>
<td>regulation of ribonuclease activity (GO:0060700)</td>
<td>29.25</td>
<td>3.16E-05</td>
</tr>
<tr>
<td>inflammatory response to wounding (GO:0090594)</td>
<td>28.21</td>
<td>3.69E-04</td>
</tr>
<tr>
<td>positive regulation of RIG-I signaling pathway (GO:1900246)</td>
<td>21.94</td>
<td>6.61E-04</td>
</tr>
<tr>
<td>positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903589)</td>
<td>21.94</td>
<td>6.61E-04</td>
</tr>
<tr>
<td>positive regulation of T cell apoptotic process (GO:0070234)</td>
<td>21.94</td>
<td>9.38E-06</td>
</tr>
<tr>
<td>type I interferon signaling pathway (GO:0034340)</td>
<td>21.61</td>
<td>5.61E-21</td>
</tr>
<tr>
<td>cellular response to type I interferon (GO:0071357)</td>
<td>21.61</td>
<td>5.61E-21</td>
</tr>
<tr>
<td>response to type I interferon (GO:0034340)</td>
<td>21.03</td>
<td>1.19E-21</td>
</tr>
</tbody>
</table>
### A) CON/Static vs CON/Stress

<table>
<thead>
<tr>
<th>GO biological process complete</th>
<th>Fold enrichment</th>
<th>Raw P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>negative regulation of viral genome replication (GO:0045071)</td>
<td>20.08</td>
<td>6.47E-17</td>
</tr>
<tr>
<td>response to interferon-alpha (GO:0035455)</td>
<td>19.20</td>
<td>3.04E-07</td>
</tr>
<tr>
<td>positive regulation of T cell differentiation in thymus (GO:0033089)</td>
<td>17.95</td>
<td>1.07E-03</td>
</tr>
<tr>
<td>positive regulation of lymphocyte apoptotic process (GO:0070230)</td>
<td>17.32</td>
<td>2.45E-05</td>
</tr>
<tr>
<td>response to interferon-beta (GO:0035456)</td>
<td>15.89</td>
<td>9.06E-07</td>
</tr>
<tr>
<td>negative regulation of viral life cycle (GO:1903901)</td>
<td>15.86</td>
<td>5.89E-17</td>
</tr>
<tr>
<td>positive regulation of interferon-alpha production (GO:0032727)</td>
<td>15.80</td>
<td>5.76E-06</td>
</tr>
<tr>
<td>regulation of interferon-alpha production (GO:0032647)</td>
<td>14.86</td>
<td>1.33E-06</td>
</tr>
<tr>
<td>cellular response to exogenous dsRNA (GO:0071360)</td>
<td>14.63</td>
<td>2.91E-04</td>
</tr>
<tr>
<td>positive regulation of monocyte chemotaxis (GO:0090026)</td>
<td>14.63</td>
<td>2.91E-04</td>
</tr>
<tr>
<td>negative regulation of viral process (GO:0048525)</td>
<td>13.44</td>
<td>1.01E-17</td>
</tr>
<tr>
<td>defense response to virus (GO:0051607)</td>
<td>13.50</td>
<td>1.65E-30</td>
</tr>
<tr>
<td>regulation of viral genome replication (GO:0045069)</td>
<td>13.30</td>
<td>5.89E-15</td>
</tr>
<tr>
<td>cellular response to interferon-beta (GO:0035458)</td>
<td>13.16</td>
<td>4.13E-04</td>
</tr>
<tr>
<td>positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050)</td>
<td>12.54</td>
<td>4.86E-04</td>
</tr>
<tr>
<td>regulation of nuclease activity (GO:0032069)</td>
<td>11.97</td>
<td>5.76E-04</td>
</tr>
<tr>
<td>fibrinolysis (GO:0042730)</td>
<td>11.97</td>
<td>5.76E-04</td>
</tr>
<tr>
<td>pyrimidine nucleoside catabolic process (GO:0046135)</td>
<td>11.45</td>
<td>6.58E-04</td>
</tr>
<tr>
<td>cellular response to dsRNA (GO:0071359)</td>
<td>11.45</td>
<td>6.58E-04</td>
</tr>
</tbody>
</table>

### B) CON/Static vs AZM/Stress

<table>
<thead>
<tr>
<th>GO biological process complete</th>
<th>Fold enrichment</th>
<th>Raw P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>cholesterol biosynthetic process via lathosterol (GO:0033490)</td>
<td>21.63</td>
<td>1.19E-03</td>
</tr>
<tr>
<td>cholesterol biosynthetic process via desmosterol (GO:0033489)</td>
<td>21.63</td>
<td>1.19E-03</td>
</tr>
<tr>
<td>smooth muscle adaptation (GO:0014805)</td>
<td>21.63</td>
<td>1.19E-03</td>
</tr>
<tr>
<td>foam cell differentiation (GO:0090077)</td>
<td>16.48</td>
<td>3.42E-04</td>
</tr>
<tr>
<td>macrophage derived foam cell differentiation (GO:0010742)</td>
<td>16.48</td>
<td>3.42E-04</td>
</tr>
<tr>
<td>low-density lipoprotein particle clearance (GO:0034383)</td>
<td>13.22</td>
<td>1.11E-08</td>
</tr>
<tr>
<td>positive regulation of Ryanodine-sensitive calcium-release channel activity (GO:0060316)</td>
<td>12.82</td>
<td>7.02E-04</td>
</tr>
<tr>
<td>skin morphogenesis (GO:0043589)</td>
<td>12.82</td>
<td>7.02E-04</td>
</tr>
<tr>
<td>chemical homeostasis within a tissue (GO:0048875)</td>
<td>11.09</td>
<td>2.48E-04</td>
</tr>
<tr>
<td>cholesterol biosynthetic process (GO:0006695)</td>
<td>10.99</td>
<td>4.63E-11</td>
</tr>
<tr>
<td>sterol biosynthetic process (GO:0016126)</td>
<td>10.82</td>
<td>3.51E-12</td>
</tr>
<tr>
<td>secondary alcohol biosynthetic process (GO:1902653)</td>
<td>10.73</td>
<td>6.15E-11</td>
</tr>
<tr>
<td>membrane raft assembly (GO:0001765)</td>
<td>10.49</td>
<td>1.27E-03</td>
</tr>
<tr>
<td>N-acetylneuraminate metabolic process (GO:0060654)</td>
<td>10.49</td>
<td>1.27E-03</td>
</tr>
<tr>
<td>surfactant homeostasis (GO:0043129)</td>
<td>10.49</td>
<td>1.27E-03</td>
</tr>
<tr>
<td>regulation of cholesterol biosynthetic process (GO:0045540)</td>
<td>10.06</td>
<td>5.10E-10</td>
</tr>
<tr>
<td>regulation of sterol biosynthetic process (GO:0106118)</td>
<td>10.06</td>
<td>5.10E-10</td>
</tr>
<tr>
<td>negative regulation of protein homooligomerization (GO:0032463)</td>
<td>9.61</td>
<td>1.65E-03</td>
</tr>
<tr>
<td>sequestering of metal ion (GO:0051238)</td>
<td>9.61</td>
<td>1.65E-03</td>
</tr>
<tr>
<td>hemidesmosome assembly (GO:0031581)</td>
<td>9.61</td>
<td>1.65E-03</td>
</tr>
<tr>
<td>phagosome acidification (GO:0090383)</td>
<td>9.27</td>
<td>2.72E-06</td>
</tr>
</tbody>
</table>
When comparing RNA sequencing of CON/Stress vs AZM/Stress, we observed that inflammation related pathways were significantly negatively correlated (Fig. 3C). Several of the pathways that were upregulated because of stress were downregulated when cells were AZM pre-treated (Fig. 3A,C).

The effect of AZM treatment alone was also explored. The positively correlated gene sets were not associated with inflammation, but there was a high negative correlation to inflammatory response and TNFα signaling via NFĸB (Fig. 3D).

Lastly, we compared AZM/Static vs AZM/Stress. The inflammatory response was present, but the NES was considerably lower compared to CON/Static vs CON/Stress. Also, fewer inflammatory related gene sets were significantly enriched (Fig. 3E).

Exploring the IFNα pathway, we set up a heat map showing 24 of the most significantly differentially expressed genes in the pathway (Fig. S31). This clearly shows the attenuating effect of AZM on gene expression.

To further investigate the gene enrichment patterns of the two conditions, we uploaded statistically significantly (P ≤ 0.05) differentially expressed genes with at least two-fold upregulation into the PANTHER gene ontology (GO) classification system (Mi et al., 2017). The outcome was two very different GO biological process analyses. Cyclical stress of untreated cell layers (CON/Stress) resulted in enrichment of inflammation-linked GO categories (Tab. 1A). Cyclically stressing AZM pre-treated cells (AZM/Stress) resulted in the top enriched GO categories being associated with lipid metabolism and skin barrier (Tab. 1B).

As the GO analyses indicated prominent type-I interferon pathway activity (fold enrichment of 21.61 and raw P-value of 5.6E-21) in the CON/Stress cell layer, we looked up the genes that were enriched in our gene set and saw that the genes involved were less differentially expressed in the AZM/Stress setting (Tab. 2). AZM-mediated immunomodulation was also detected when important immunity markers (cytokines/chemokines, toll-like receptors, matrix...
metalloproteases and TNF super family) were tested in the data-
sets of both conditions (Tab. 3). Only significantly differentially ex-
pressed genes are shown (P ≤ 0.05). CON/Stress cell layers tend-
ted to show considerable differential expression of selected immune
genes, whereas AZM/Stress cell layers showed fewer differentially expressed genes (Tab. 3).

3.3 AZM attenuates stress-induced inflammatory response in bronchial epithelial cell layers – immunostaining analysis

As the gene enrichment analysis showed high enrichment scores for TNFα signaling via NFκB, we analyzed the effects of AZM-pretreatment on NFκB localization in VA10 cells. Cell layers were immunostained for NFκB and viewed using a confocal microscope. Using the co-localization feature of the Olympus flouview software, we observed that NFκB translocation to the nucleus was increased in CON/Stress cell layers, compared to CON/Static cell layers (Fig. 4A, upper). Compared to CON/ Stress cell layers, the NFκB nuclear translocation was attenuated in AZM/Stress conditions (Fig. 4A, lower).

As NFκB nucleus translocation is usually preceded by a break-
down of IκB, we investigated the expression of IκB. Western blot-
ting revealed no changes in IκB protein level, indicating non-ca-
nonical NFκB pathway activation (Sun, 2017) (Fig. S41).

On transcriptional level, we had seen that the expression of pro-inflammatory cytokine CXCL8 was decreased by AZM pre-treatment (AZM/Static), but significantly increased upon me-
chanically stressing the cells (CON/Stress). The combined ef-
fact of AZM pre-treatment and mechanically stressing the cells (AZM/Stress) resulted in non-significant changes (Fig. 4B). This was substantiated on a protein level by detection of IL-8 release by ELISA, which showed the same pattern as the gene expression (Fig. 4C).

3.4 YKL-40 is modulated in both cyclically stressed and AZM treated bronchial lung cell layers

As YKL-40 is an emerging inflammatory marker (Dela Cruz et al., 2012; Libreros et al., 2013) that has been implicated in immu
nomodulation (Kastrup, 2012; Ling and Recklies, 2004) and tissue remodeling (Lee et al., 2011), and as a follow up to our previous study (Joelsson et al., 2019) showing increased expression of YKL-40 due to mechanical stress in bronchial cell lay-
ers, we analyzed the effects of AZM pre-treatment on YKL-40.
YKL-40 immunofluorescent staining was increased upon me-
chanical stress in VA10 cell layers (CON/Stress) compared to
CON/Static (Fig. 5A, upper). AZM pretreatment also increased YKL-40 protein staining (AZM/Static); this was not further in-
creased by mechanical stress (AZM/Stress) (Fig. 5A, lower).

Pixel intensity quantifications are shown in Figure S51. In line, Western blots in VA10 ALI cultured cells showed an increase in
YKL-40 protein in CON/Stress compared to CON/Static condi-
tions, as we had shown previously (Joelsson et al., 2019). The
increase in YKL-40 protein was more pronounced in AZM/Stat-
ic cells with no further increase in AZM/Stress cells (Fig. 5B
and Fig. S61). Immunohistochemical staining of YKL-40 in un-
treated cells, and in AZM pre-treated cells, showed an increase

![Log2 of Fold change](#)
in YKL-40 expression along with a thickening of the cell layer (Fig. 5D), as seen in AZM treated cell layers before (Arason et al., 2019).

The expression of CHI3L1 (gene for YKL-40) increased in CON/Stress as well as AZM/Static cells (Fig. 5C). However, in comparison, the gene expression in AZM/Stress cells was much higher, indicating a co-operative effect. CHI3L1 differential expression was confirmed by RNA sequencing. Expression was increased 1.8-fold in CON/Stress versus CON/Static conditions and 10.2-fold in AZM/Stress versus CON/Static conditions (Fig 5E).

4 Discussion

Clinically, barrier failure of the epithelium is associated with inflammation and excessive cytokine signaling, aggravating the clinical symptoms of the patient, as immune cells from the surrounding blood vessels are overly active, resulting in excessive inflammatory responses (Slutsky and Ranieri, 2013). The immunomodulatory effects of macrolides are gaining interest in this respect (Zimmermann et al., 2018). AZM in particular has been linked to reducing the production of pro-inflammatory cytokines and promoting the resolution of chronic inflammation (Cramer et al., 2017).

Alveolar and bronchial lung cell layers subjected to CPAD stress showed a disrupted barrier, characterized by loss of grid-like formation with aggregated and disorganized actin fibers along with a reduction of important junctional proteins, i.e., E-cadherin. We observed that upon pre-treatment with AZM, barrier integrity was maintained during cyclical stress in the CPAD. An increase in vesicle and lamellar body formations was seen when untreated cells were mechanically stressed. As expected (Arason et al., 2019), AZM pre-treatment already increased lamellar body formation, which is associated with barrier integrity in the epidermis. When AZM pre-treated cells then were stressed in the CPAD, an
exaggerated lamellar body formation response was observed, indicating that lamellar body formation under pressure might be a protective response to injury. With the addition of AZM, this response was augmented to the extent that a functional barrier was maintained.

Importantly, we saw that cyclical stress induces SFPB expression both in untreated VA10 and hAELVi cell lines. In line, we reported earlier that SFPB gene expression both in untreated VA10 cells in response to stress in the CPAD (Joelsson et al., 2019). For the hAELVi cell line, this could indicate a sub-population of alveolar type II cells within the cell culture. In these cells, the AZM pre-treatment resulted in slightly increased SFPB expression, possibly due to activation of these type II cells, but no further increase was detected after cyclical stressing the cells. Surfactant production has been linked to prognosis in pulmonary diseases (Delgado et al., 2015; Han and Mallampalli, 2015). As no further surfactant production was seen in AZM-treated mechanically stressed cells, we postulate that this might indicate a protective mechanism where surfactant production is not as readily triggered by injury in AZM-treated cells.

Upon analyzing RNA sequencing data of the bronchial VA10 cells, where we compared the gene expression profiles of all the conditions tested, we found that when stress was the only factor, GSEA showed a strong positive correlation to many immune-related gene sets. However, GSEA in AZM/Stress cell layers showed considerably lower NES in the same immune related gene sets, indicating an attenuated inflammation response. When we compared CON/Stress cells with AZM/Stress cells, we observed that AZM treatment resulted in negative correlation with a number of inflammation related pathways. In fact, inflammatory response gene sets, along with TNFα signaling via NFκB, were negatively correlated when AZM pre-treatment was the only factor. A similar effect was observed when differentially expressed genes were analyzed by PANTHER, another GO data-base. Overrepresented inflammation and immune related GO categories seen in CON/Stress cells were not seen in AZM/Stress cells, being replaced by fatty acid metabolism- and barrier-related GO categories. When immune markers, i.e., cytokines/chemokines, toll-like receptors, matrix metalloproteases and TNF superfamily were checked in the RNA sequencing data, the number of genes significantly differentially expressed because of cyclical stress was markedly reduced when cells had been pre-treated with AZM, indicating a dampening of the immune response.

AZM pre-treatment of bronchial lung epithelial cells resulted in significant downregulation of TNF and CXCL8, key effectors of inflammatory response (Lawrence, 2009). In this work, we...
show that CPAD mechanical stressing of bronchial epithelial cells results in increased NFκB localization to the nucleus and an increase in IL8 expression on the RNA and protein level. Conversely, pre-treatment with AZM attenuated the NFκB/nucleus co-localization and IL8 expression in CPAD stressed cells. When AZM pre-treated cells were stressed, we no longer saw significant increases in IL8 expression as seen in the CON/Stress cells. We did not observe reduced levels of IκB (Fig. S44), indicating that the non-canonical pathway is activated, in which NFκB translocation does not depend on IκB breakdown (Sun, 2017).

As barrier failure and an inappropriate inflammatory response are connected, and there is likely remodeling of tissue in response to injury (Lee et al., 2011), we also investigated the inflammation-related marker YKL-40 in our model. YKL-40 protein was increased comparably both in CON/Stress and AZM/Static conditions versus CON/Static; whereas there was no further increase of YKL-40 in AZM/Stress versus AZM/Static conditions. The AZM-induced YKL-40 protein was evenly distributed, whereas YKL-40 in the CON/Stress condition showed a more erratic pattern. The YKL-40 protein data were confirmed by gene expression data. The mechanisms of YKL-40 are still being deciphered. The data presented in this study support the indications of a cytotoxic role for this molecule, as has been suggested before (Majewski et al., 2019).

We have previously used TEER as a marker for epithelial barrier in ALI culture (Joelsson et al., 2019). In the current study, TEER did not decrease after stressing the cells. Indeed, after stressing the cells, TEER showed a high variation between measurements. Thus, TEER was an unreliable marker for barrier integrity in the CPAD condition. This might be explained by the mechanical effects on the cell layer, causing formation of cell aggregates in some instances and tears in the layer in others.

The hAEVLi cell line is characterized as alveolar type I, but, interestingly, it showed expression of surfactant protein B in the CPAD, which is a characteristic of type II cells. This phenotype was induced in the cell line during mechanical stress or by AZM treatment. We aim to follow this up as well as to compare the effect of AZM on gene and protein levels to that on VAO10 cells in future studies.

The CPAD aims to reduce and replace animal experiments by modeling mechanical ventilation induced lung injury in human cells. This study confirms the relevance of the model as the clinical effects of AZM can be reproduced and investigated mechanistically in the CPAD. It is desirable that alternatives to animal experiments also aim to replace animal-derived components such as antibodies from ascites fluid, with non-animal alternatives. This can be challenged when the composition of media or the origin of components is not disclosed by the companies selling them. We will investigate whether substitutes are available in future studies.

Long-term use of AZM has been widely practiced in clinical treatment and in clinical trials of patients with serious chronic lung diseases and ARDS without full understanding of its pharmacologic mechanisms (Kawamura et al., 2016). It even has been proposed to be the “Holy Grail” to prevent exacerbation in chronic respiratory diseases (Welte, 2019) although the antibiotic aspect of AZM can lead to increased macroide resistance (Taylor et al., 2019). The information provided in this paper may be an important step towards understanding the biological pathways that underlie the effects of AZM and might be utilized to develop drugs without antibacterial activity that influence barrier integrity and modulate inflammatory response. These could be screened and characterized in the CPAD model and compared to AZM to reduce and replace animal experiments.

Overall, the findings of this study show that AZM pre-treatment maintains barrier integrity in mechanically stressed bronchial and alveolar cell layers and shows a robust anti-inflammatory modulation in bronchial cell layers.

References


Gibson, P. G., Yang, I. A., Upham, J. W. et al. (2017). Effect of azithromycin on asthma exacerbations and quality of life in


Slutsky, A. S. and Ranieri, V. M. (2013). Ventilator-induced lung...


**Conflict of interest**
The authors declare that GHG, TG, FL and CPP work for and/or are shareholders in EpiEndo Pharmaceuticals.

**Funding**
This work was supported by the Icelandic Research Council (Rannís grant numbers: 195872-051) and the Landspitali University Hospital science fund.

**Acknowledgements**
We thank Johann Arnfinnsson and Paulina Cherek for their assistance in preparing TEM samples. We thank Bryndis Valdimarsdottir for her assistance with paraffin embedding.